Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
94
-
Total 13F shares, excl. options
-
51M
-
Shares change
-
-3.18M
-
Total reported value, excl. options
-
$193M
-
Value change
-
-$11.4M
-
Put/Call ratio
-
0.42
-
Number of buys
-
45
-
Number of sells
-
-37
-
Price
-
$3.78
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q3 2018
114 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q3 2018.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 94 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51M shares
of 123M outstanding shares and own 41.38% of the company stock.
Largest 10 shareholders include BlackRock Inc. (6.25M shares), Consonance Capital Management LP (6.04M shares), Broadfin Capital, LLC (5.14M shares), venBio Select Advisor LLC (4.5M shares), Vanguard Group Inc (4.46M shares), BAKER BROS. ADVISORS LP (2.9M shares), MORGAN STANLEY (1.75M shares), MANGROVE PARTNERS (1.68M shares), ARMISTICE CAPITAL, LLC (1.67M shares), and Sofinnova Ventures Inc (1.55M shares).
This table shows the top 94 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.